These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32610904)

  • 1. Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer.
    Yao H; Xie S; Ma X; Liu J; Wu H; Lin A; Yao H; Li D; Xu S; Yang DH; Chen ZS; Xu J
    J Med Chem; 2020 Aug; 63(15):8157-8178. PubMed ID: 32610904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5.
    Wu J; Ding Y; Chen CH; Zhou Z; Ding C; Chen H; Zhou J; Chen C
    Cancer Lett; 2016 Oct; 380(2):393-402. PubMed ID: 27387452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin.
    Liu J; Xie S; Shao X; Xue S; Du P; Wu H; Xu S; Chen ZS; Yang DH; Xu J; Yao H
    Eur J Med Chem; 2022 Mar; 231():114155. PubMed ID: 35121201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.
    Xu S; Yao H; Luo S; Zhang YK; Yang DH; Li D; Wang G; Hu M; Qiu Y; Wu X; Yao H; Xie W; Chen ZS; Xu J
    J Med Chem; 2017 Feb; 60(4):1449-1468. PubMed ID: 28165738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 8,9-seco-
    Fan RZ; Chen L; Su T; Li W; Huang JL; Sang J; Tang GH; Yin S
    J Med Chem; 2021 Jul; 64(14):9926-9942. PubMed ID: 34236840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility.
    Ding C; Zhang Y; Chen H; Yang Z; Wild C; Chu L; Liu H; Shen Q; Zhou J
    J Med Chem; 2013 Jun; 56(12):5048-58. PubMed ID: 23746196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel cystathionine γ-lyase inhibitor, I194496, inhibits the growth and metastasis of human TNBC via downregulating multiple signaling pathways.
    Liu Y; Wang L; Zhang X; Deng Y; Pan L; Li H; Shi X; Wang T
    Sci Rep; 2021 Apr; 11(1):8963. PubMed ID: 33903672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationship study of a potent MHO7 analogue as potential anti-triple negative breast cancer agent.
    Liang JJ; Yu WL; Yang L; Qin KM; Yin YP; Li D; Ni YH; Yan JJ; Zhong YX; Deng ZX; Hong K
    Eur J Med Chem; 2022 Jun; 236():114313. PubMed ID: 35390712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oridonin inhibits 4T1 tumor growth by suppressing Treg differentiation via TGF-β receptor.
    Guo J; Chen T; Ma Z; Qiao C; Yuan F; Guo X; Liu J; Shen Y; Yu L; Xiang A
    Int Immunopharmacol; 2020 Nov; 88():106831. PubMed ID: 32853925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer.
    Liu D; Cardillo TM; Wang Y; Rossi EA; Goldenberg DM; Chang CH
    Mol Cancer; 2014 Mar; 13():53. PubMed ID: 24606732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
    Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
    Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oridonin inhibits mTOR signaling and the growth of lung cancer tumors.
    Wang YY; Lv YF; Lu L; Cai L
    Anticancer Drugs; 2014 Nov; 25(10):1192-200. PubMed ID: 25075795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regio- and Stereospecific Synthesis of Oridonin D-Ring Aziridinated Analogues for the Treatment of Triple-Negative Breast Cancer via Mediated Irreversible Covalent Warheads.
    Ding Y; Li D; Ding C; Wang P; Liu Z; Wold EA; Ye N; Chen H; White MA; Shen Q; Zhou J
    J Med Chem; 2018 Apr; 61(7):2737-2752. PubMed ID: 29528645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
    Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oridonin inhibits hypoxia-induced epithelial-mesenchymal transition and cell migration by the hypoxia-inducible factor-1α/matrix metallopeptidase-9 signal pathway in gallbladder cancer.
    Chen K; Ye J; Qi L; Liao Y; Li R; Song S; Zhou C; Feng R; Zhai W
    Anticancer Drugs; 2019 Oct; 30(9):925-932. PubMed ID: 31517732
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Ning J; Zhan N; Wu Z; Li Y; Zhang D; Shi Y; Zhou Y; Chen CH; Jin W
    RSC Med Chem; 2024 Aug; 15(11):3674-94. PubMed ID: 39246742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
    Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
    Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.